A Randomized Controlled Trial of Aspirin in Patients With Abnormal Uterine Artery Blood Flow

Morris, Jonathan M.; Fay, Roger A.; Ellwood, David; Cook, Colleen-M.; Devonald, Katherine J.

doi:10.1016/0029-7844(95)00340-1

Cited by 65 publications

(34 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low dose acetylsalicylic acid (ASA) is a drug that decreases thromboxane production without reducing the prostacyclin production (22), preventing vasoconstriction and coagulation problems which are the characteristic of preeclampsia (23). Administration of ASA is safe for both mother and fetus (24)(25)(26). The proposed ASA dosage varies between 60-150 mg per day and has been initiated between 13 to 26 weeks of pregnancy in different studies (22,27,28).…”

Section: Introductionmentioning

confidence: 99%

Aspirin and Preeclampsia Prevention in Patients With Abnormal Uterine Artery Blood Flow

Talari¹,

Mesdaghinia²,

Abedzadeh-Kalahroudi³

2014

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Preeclampsia is one of the leading causes of maternal mortality and morbidity. Its prevalence varies between 10-25% among high-risk pregnant patients. Objectives: The aim of this study was to determine whether treatment with acetylsalicylic acid (ASA) reduces the incidence of preeclampsia among pregnant women with abnormal uterine artery flow. Patients and Methods:In this double-blind, placebo controlled trial, 80 high-risk pregnant women with preeclampsia, who had abnormal findings on Doppler ultrasonography at 12-16 weeks of pregnancy (unilateral notch with RI ≥ 0.65 or bilateral notch with RI ≥ 0.55), were randomly divided into two groups; the intervention group was treated with ASA tablet 80 mg, one tablet per day, and the control group was given placebo. Then patients were followed until the end of their pregnancy period, and pregnancy outcomes, including development of preeclampsia, the intrauterine growth retardation (IUGR), prematurity, type of delivery, birth weight, and Apgar score at one and five minutes were assessed. Data were analyzed using the student's t-test, chi-square or Fisher's exact test, and multivariate logistic regression. P values less than 0.05 were considered statistically significant. Results: There were no significant differences between the two groups in terms of baseline characteristics. There was a significant difference between the ASA and placebo groups in the incidence of preeclampsia (2.5% versus 22.5%), adjusting for the neonatal and maternal covariates. Conclusions: ASA prophylaxis can be used for prevention of preeclampsia in high-risk patients with abnormal uterine artery.

show abstract

Section: Introductionmentioning

confidence: 99%

Aspirin and Preeclampsia Prevention in Patients With Abnormal Uterine Artery Blood Flow

Talari¹,

Mesdaghinia²,

Abedzadeh-Kalahroudi³

2014

Iran Red Crescent Med J

View full text Add to dashboard Cite

show abstract

“…We found ten relevant randomised trials [5][6][7][8][9][10][11][12][13][14] (summarised in Tables 2 and 3) and a systematic review. 22 The systematic review needed to be updated, 22 as several trials had been published since the publication of the review.…”

Section: Randomised Trials Of Uterine Artery Doppler Test and Aspirinmentioning

confidence: 99%

“…The eight trials that have used this design cannot therefore give any clarity on whether the UAD test should be used as a test in practice. [5][6][7][8][9][10][11][12] Design B, on the other hand, offers an assessment of the UAD test and aspirin therapy combination, as women are randomised to Doppler or no Doppler groups, with treatment of the Doppler positive women in the Doppler arm. It addresses the question: does testing with UAD plus aspirin for test-positive cases prevent pre-eclampsia?…”

Section: Critical Evaluation Of Trial Designs Involving Testsmentioning

confidence: 99%

“…22 The systematic review needed to be updated, 22 as several trials had been published since the publication of the review. In eight studies, [5][6][7][8][9][10][11][12] the UAD test was used to select high-risk women who were then randomised to treatment with aspirin or placebo (referred to as design A; Figure 1A). In the other two trials, 13,14 women were randomised to either a strategy of being screened with the UAD test, with aspirin treatment for test-positive women, or to not being screened with the UAD test, with aspirin treatment given according to a policy not based on UAD testing (referred to as design B; Figure 1B).…”

Section: Randomised Trials Of Uterine Artery Doppler Test and Aspirinmentioning

confidence: 99%

“…We use the example of the UAD test for pre-eclampsia to demonstrate how this confusion can lead to conflicting conclusions and subsequent difficulty in producing recommendations for clinical practice. [5][6][7][8][9][10][11][12][13][14] We seek to clarify this confusion, and describe how to avoid these pitfalls.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

How to interpret randomised trials of test–treatment combinations: a critical evaluation of research on uterine Doppler test to predict, and aspirin to prevent, pre‐eclampsia

Fox

Khan

Coomarasamy

2010

BJOG

View full text Add to dashboard Cite

The methodology to evaluate either a test or treatment is well developed and understood. However, the design, conduct and interpretation of a combination of a test and a treatment in a single study are fraught with complexities. There are two distinct study designs to evaluate test-treatment combinations, with randomisation occurring either before or after the test. We present critical issues that need to be considered when evaluating and appraising test-treatment combinations, using the example of research on the uterine artery Doppler test to predict, and aspirin to prevent, pre-eclampsia.

show abstract

Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality

Henderson

Vesco

Senger

et al. 2021

JAMA

123

View full text Add to dashboard Cite

IMPORTANCE Preeclampsia is a hypertensive disorder of pregnancy that poses serious maternal and infant health risks. Previous systematic reviews have established benefits of low-dose aspirin taken during pregnancy to prevent preeclampsia and its sequelae.OBJECTIVE To update evidence for the US Preventive Services Task Force (USPSTF) on effectiveness of aspirin use in preventing preeclampsia in individuals at increased risk based on clinical risk factors or measurements associated with higher disease incidence than in the general population.

show abstract

A Randomized Controlled Trial of Aspirin in Patients With Abnormal Uterine Artery Blood Flow

Abstract: Abnormal uteroplacental resistance at 18 weeks' gestation was associated with a significant increase in adverse pregnancy outcome. Low-dose aspirin did not reduce pregnancy complications in women with uteroplacental insufficiency.

Cited by 65 publications

References 14 publications

Aspirin and Preeclampsia Prevention in Patients With Abnormal Uterine Artery Blood Flow

Aspirin and Preeclampsia Prevention in Patients With Abnormal Uterine Artery Blood Flow

How to interpret randomised trials of test–treatment combinations: a critical evaluation of research on uterine Doppler test to predict, and aspirin to prevent, pre‐eclampsia

Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality

Contact Info

Product

Resources

About